191 related articles for article (PubMed ID: 19051610)
1. Polymorphism of dextromethorphan oxidation in Polish population.
Skretkowicz J; Wojtczak A; Rychlik-Sych M
Acta Pol Pharm; 2008; 65(5):611-5. PubMed ID: 19051610
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India.
Abraham BK; Adithan C; Kiran PU; Asad M; Koumaravelou K
Acta Pharmacol Sin; 2000 Jun; 21(6):494-8. PubMed ID: 11360682
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 phenotyping with dextromethorphan.
Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
Cai W; Chen B; Tao X; Ling S; Zhang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
[TBL] [Abstract][Full Text] [Related]
5. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of dextromethorphan oxidation in South Indian subjects.
Mamidi RN; Satyavageeswaran S; Vakkalanka SV; Chaluvadi MR; Katneni K; Brahmadevara N; Damodarram G; Subramaniam S
Clin Pharmacol Ther; 1999 Aug; 66(2):193-200. PubMed ID: 10460073
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
[TBL] [Abstract][Full Text] [Related]
8. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
[TBL] [Abstract][Full Text] [Related]
9. Oxidative phenotype status in related subjects.
Rychlik-Sych M; Łyczba M; Skretkowicz J
Acta Pol Pharm; 2008; 65(1):165-8. PubMed ID: 18536192
[TBL] [Abstract][Full Text] [Related]
10. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
12. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
13. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
[TBL] [Abstract][Full Text] [Related]
14. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
17. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
18. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
[TBL] [Abstract][Full Text] [Related]
19. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Ozdemir M; Crewe KH; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2004 Dec; 44(12):1398-404. PubMed ID: 15545311
[TBL] [Abstract][Full Text] [Related]
20. Enzyme polymorphism on the metabolic O-demethylation of dextromethorphan in a South American population.
Estévez F; Giusti M; Parrillo S; Oxandabarat J
Medicina (B Aires); 1996; 56(4):378-82. PubMed ID: 9138342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
